Pim-1 knockdown potentiates paclitaxel-induced apoptosis in human hormone-refractory prostate cancers through inhibition of NHEJ DNA repair

Cancer Letters

Volumn 319, Issue 2, 2012, Pages 214-222

  Hsu, Jui Ling ^a   Leong, Pui Kei ^a   Ho, Yunn Fang ^a   Hsu, Lih Ching ^a   Lu, Pin Hsuan ^a   Chen, Ching Shih ^b   Guh, Jih Hwa ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

H2A.X phosphorylation; NHEJ DNA repair; Paclitaxel; Pim 1; Prostate cancers

Indexed keywords

ATM PROTEIN; HISTONE H2AX; KU ANTIGEN; KU80 ANTIGEN; PACLITAXEL; PROTEIN KINASE PIM 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA END JOINING REPAIR; DOWN REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DNA END-JOINING REPAIR; DNA HELICASES; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; GENE KNOCKDOWN TECHNIQUES; HISTONES; HUMANS; MALE; MICROTUBULES; PACLITAXEL; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-PIM-1;

EID: 84862793343     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.01.004     Document Type: Article

References (38)

1. Wang Z., Bhattacharya N., Weaver M., Petersen K., Meyer M., Gapter L., Magnuson N.S. Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J. Vet. Sci. 2001, 2:167-179.
2. Chen L.S., Balakrishnan K., Gandhi V. Inflammation and survival pathways: chronic lymphocytic leukemia as a model system. Biochem. Pharmacol. 2010, 80:1936-1945.
3. Shah N., Pang B., Yeoh K.G., Thorn S., Chen C.S., Lilly M.B., Salto-Tellez M. Potential roles for the PIM1 kinase in human cancer - a molecular and therapeutic appraisal. Eur. J. Cancer 2008, 44:2144-2151.
4. Qian K.C., Wang L., Hickey E.R., Studts J., Barringer K., Peng C., Kronkaitis A., Li J., White A., Mische S., Farmer B. Structural basis of constitutive activity and a unique nucleotide binding mode of human PIM1 kinase. J. Biol. Chem. 2005, 280:6130-6137.
5. Bachmann M., Kosan C., Xing P.X., Montenarh M., Hoffmann I., Moroy T. The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C. Int. J. Biochem. Cell Biol. 2006, 38:430-433.
6. Wang Z., Bhattacharya N., Mixter P.F., Wei W., Sedivy J., Magnuson N.S. Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim. Biophys. Acta 2002, 1593:45-55.
7. Morishita D., Katayama R., Sekimizu K., Tsuruo T., Fujita N. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res. 2008, 68:5076-5085.
8. Valdman A., Fang X., Pang S.T., Ekman P., Egevad L. Pim-1 expression in prostatic intraepithelial neoplasia and human prostate cancer. Prostate 2004, 60:367-371.
9. Bachmann M., Möröy T. The serine/threonine kinase Pim-1. Int. J. Biochem. Cell Biol. 2005, 37:726-730.
10. Aho T.L., Lund R.J., Ylikoski E.K., Matikainen S., Lahesmaa R., Koskinen P.J. Expression of human PIM family genes is selectively up-regulated by cytokines promoting T helper type 1, but not T helper type 2, cell differentiation. Immunology 2005, 116:82-88.
11. Le Q.T., Denko N.C., Giaccia A.J. Hypoxic gene expression and metastasis. Cancer Metast. Rev. 2004, 23:293-310.
12. Zemskova M., Sahakian E., Bashkirova S., Lilly M. The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. J. Biol. Chem. 2008, 283:20635-20644.
13. Warnecke-Eberz U., Bollschweiler E., Drebber U., Metzger R., Baldus S.E., Hölscher A.H., Mönig S. Prognostic impact of protein overexpression of the proto-oncogene PIM-1 in gastric cancer. Anticancer Res. 2009, 29(11):4451-4455.
14. Reiser-Erkan C., Erkan M., Pan Z., Bekasi S., Giese N.A., Streit S., Michalski C.W., Friess H., Kleeff J. Hypoxia-inducible proto-oncogene Pim-1 is a prognostic marker in pancreatic ductal adenocarcinoma. Cancer Biol. Ther. 2008, 7:1352-1359.
15. Xu Y., Zhang T., Tang H., Zhang S., Liu M., Ren D., Niu Y. Overexpression of PIM-1 is a potential biomarker in prostate carcinoma. J. Surg. Oncol. 2005, 92:326-330.
16. Brault L., Gasser C., Bracher F., Huber K., Knapp S., Schwaller J. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica 2010, 95:1004-1015.
17. Holder S., Zemskova M., Zhang C., Tabrizizad M., Bremer R., Neidigh J.W., Lilly M.B. Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase. Mol. Cancer Ther. 2007, 6:163-172.
18. Fedorov O., Marsden B., Pogacic V., Rellos P., Muller S., Bullock A.N., Schwaller J., Sundström M., Knapp S. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc. Natl. Acad. Sci. USA 2007, 104:20523-20528.
19. Lin Y.W., Beharry Z.M., Hill E.G., Song J.H., Wang W., Xia Z., Zhang Z., Aplan P.D., Aster J.C., Smith C.D., Kraft A.S. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood 2010, 115:824-833.
20. Macdonald A., Campbell D.G., Toth R., McLauchlan H., Hastie C.J., Arthur J.S. Pim kinases phosphorylate multiple Bcl-XL. BMC Cell Biol. 2006, 7:1-14.
21. Lilly M., Sandholm J., Cooper J.J., Koskinen P.J., Kraft A. The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway. Oncogene 1999, 18:4022-4031.
22. Chen W.W., Chan D.C., Donald C., Lilly M.B., Kraft A.S. Pim family kinases enhance tumor growth of prostate cancer cells. Mol. Cancer Res. 2005, 3:443-451.
23. Zhang F., Beharry Z.M., Harris T.E., Lilly M.B., Smith C.D., Mahajan S., Kraft A.S. PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells. Cancer Biol. Ther. 2009, 8:846-853.
24. Lilly M., Kraft A. Enforced expression of the Mr 33,000 Pim-1 kinase enhances factor-independent survival and inhibits apoptosis in murine myeloid cells. Cancer Res. 1997, 57:5348-5355.
25. Xie Y., Xu K., Dai B., Guo Z., Jiang T., Chen H., Qiu Y. The 44kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs. Oncogene 2006, 25:70-78.
26. Aho T.L., Sandholm J., Peltola K.J., Mankonen H.P., Lilly M., Koskinen P.J. Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett. 2004, 571:43-49.
27. Yuan J., Adamski R., Chen J. Focus on histone variant H2AX: to be or not to be. FEBS Lett. 2010, 584:3717-3724.
28. Stewart G.D., Nanda J., Katz E., Bowman K.J., Christie J.G., Brown D.J., McLaren D.B., Riddick A.C., Ross J.A., Jones G.D., Habib F.K. DNA strand breaks and hypoxia response inhibition mediate the radiosensitisation effect of nitric oxide donors on prostate cancer under varying oxygen conditions. Biochem. Pharmacol. 2011, 81:203-210.
29. Allen C., Ashley A.K., Hromas R., Nickoloff J.A. More forks on the road to replication stress recovery. J. Mol. Cell Biol. 2011, 3:4-12.
30. Seluanov A., Danek J., Hause N., Gorbunova V. Changes in the level and distribution of Ku proteins during cellular senescence. DNA Repair (Amst) 2007, 6:1740-1748.
31. Casagrande R., Georgetti S.R., Verri W.A., Jabor J.R., Santos A.C., Fonseca M.J. Evaluation of functional stability of quercetin as a raw material and in different topical formulations by its antilipoperoxidative activity. AAPS Pharm. Sci. Technol. 2006, 7:E10.
32. Walker S.R., Chaudhury M., Nelson E.A., Frank D.A. Microtubule-binding chemotherapeutic agents inhibit signal transducer and activator of transcription 3 (STAT3) signaling. Mol. Pharmacol. 2010, 78:903-908.
33. Branham M.T., Nadin S.B., Vargas-Roig L.M., Ciocca D.R. DNA damage induced by paclitaxel and DNA repair capability of peripheral blood lymphocytes as evaluated by the alkaline comet assay. Mutat. Res. 2004, 560:11-17.
34. Celeste A., Fernandez-Capetillo O., Kruhlak M.J., Pilch D.R., Staudt D.W., Lee A., Bonner R.F., Bonner W.M., Nussenzweig A. Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks. Nat. Cell Biol. 2003, 5:675-679.
35. Yuan J., Chen J. MRE11-RAD50-NBS1 complex dictates DNA repair independent of H2AX. J. Biol. Chem. 2010, 285:1097-1104.
36. Guo L., Liu X., Jiang Y., Nishikawa K., Plunkett W. DNA-PK and ATM promote cell survival in response to NK314, a topoisomerase II-alpha inhibitor. Mol. Pharmacol. 2011, 80:321-327.
37. Mumenthaler S.M., Ng P.Y., Hodge A., Bearss D., Berk G., Kanekal S., Redkar S., Taverna P., Agus D.B., Jain A. Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol. Cancer Ther. 2009, 8:2882-2893.
38. Angèle S., Falconer A., Foster C.S., Taniere P., Eeles R.A., Hall J. ATM protein overexpression in prostate tumors: possible role in telomere maintenance. Am. J. Clin. Pathol. 2004, 121:231-236.